HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alicia A Goyeneche Selected Research

Mifepristone (RU 486)

11/2021Anticancer effects of mifepristone on human uveal melanoma cells.
4/2019Advanced assessment of migration and invasion of cancer cells in response to mifepristone therapy using double fluorescence cytochemical labeling.
1/2018Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin.
1/2016Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors.
1/2014Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity.
1/2013Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics.
6/2012Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.
6/2012Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.
5/2011Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.
3/2009Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Alicia A Goyeneche Research Topics

Disease

9Ovarian Neoplasms (Ovarian Cancer)
12/2021 - 06/2007
7Neoplasms (Cancer)
12/2021 - 03/2009
2Starvation
01/2006 - 06/2003
1Disease Progression
12/2021
1Meningioma (Meningiomas)
11/2021
1Uveal melanoma
11/2021
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2018
1Ovarian Epithelial Carcinoma
06/2007
1Carcinoma (Carcinomatosis)
06/2007

Drug/Important Bio-Agent (IBA)

12Mifepristone (RU 486)FDA Link
11/2021 - 06/2007
8Cytostatic AgentsIBA
04/2019 - 06/2007
7SteroidsIBA
01/2016 - 06/2007
5PlatinumIBA
12/2021 - 02/2009
5Cisplatin (Platino)FDA LinkGeneric
01/2018 - 02/2009
4Proteins (Proteins, Gene)FDA Link
12/2021 - 01/2006
3Pharmaceutical PreparationsIBA
12/2021 - 04/2019
2Proteasome Endopeptidase Complex (Proteasome)IBA
12/2021 - 01/2016
2DNA (Deoxyribonucleic Acid)IBA
01/2018 - 05/2011
2Paclitaxel (Taxol)FDA LinkGeneric
01/2014 - 06/2012
1Anti-HIV Agents (AIDS Drugs)IBA
12/2021
1Nelfinavir (Viracept)FDA Link
12/2021
1Actins (F Actin)IBA
04/2019
1GlucocorticoidsIBA
01/2018
1Progestins (Progestagens)IBA
01/2018
1Transcription Factor CHOPIBA
01/2016
1Endoplasmic Reticulum Chaperone BiPIBA
01/2016
1CCAAT-Enhancer-Binding ProteinsIBA
01/2016
1Glucose (Dextrose)FDA LinkGeneric
01/2016
1Taxoids (Taxanes)IBA
01/2014
1taxaneIBA
06/2012
1Contraceptive Agents (Contraceptives)IBA
06/2012
1ulipristalIBA
06/2012
1Org 31710IBA
06/2012
1Cyclin-Dependent Kinase 2IBA
06/2012
1Hormones (Hormone)IBA
05/2011
1Progesterone Receptors (Progesterone Receptor)IBA
05/2011
1Caspase 3 (Caspase-3)IBA
01/2006
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2006
1Coloring Agents (Dyes)IBA
01/2006
1Hematoxylin (Haematoxylon)IBA
01/2006
1Caspase 9IBA
01/2006
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
01/2006
1ProlactinIBA
06/2003

Therapy/Procedure

6Therapeutics
12/2021 - 06/2007
2Drug Therapy (Chemotherapy)
06/2012 - 03/2009
1Cytoreduction Surgical Procedures
06/2012